CA1168150A - Conjugats d'albumine et d'agents therapeutiques - Google Patents

Conjugats d'albumine et d'agents therapeutiques

Info

Publication number
CA1168150A
CA1168150A CA000392658A CA392658A CA1168150A CA 1168150 A CA1168150 A CA 1168150A CA 000392658 A CA000392658 A CA 000392658A CA 392658 A CA392658 A CA 392658A CA 1168150 A CA1168150 A CA 1168150A
Authority
CA
Canada
Prior art keywords
albumin
enzyme
therapeutic agent
linking
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000392658A
Other languages
English (en)
Inventor
Mark J. Poznansky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Alberta
Original Assignee
University of Alberta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Alberta filed Critical University of Alberta
Priority to CA000392658A priority Critical patent/CA1168150A/fr
Application granted granted Critical
Publication of CA1168150A publication Critical patent/CA1168150A/fr
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA000392658A 1981-12-18 1981-12-18 Conjugats d'albumine et d'agents therapeutiques Expired CA1168150A (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA000392658A CA1168150A (fr) 1981-12-18 1981-12-18 Conjugats d'albumine et d'agents therapeutiques

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA000392658A CA1168150A (fr) 1981-12-18 1981-12-18 Conjugats d'albumine et d'agents therapeutiques

Publications (1)

Publication Number Publication Date
CA1168150A true CA1168150A (fr) 1984-05-29

Family

ID=4121650

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000392658A Expired CA1168150A (fr) 1981-12-18 1981-12-18 Conjugats d'albumine et d'agents therapeutiques

Country Status (1)

Country Link
CA (1) CA1168150A (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987003205A1 (fr) * 1985-11-22 1987-06-04 Coral Sociedade Brasileira De Pesquisas E Desenvol Anticorps couples a une enzyme
FR2603287A1 (fr) * 1986-06-02 1988-03-04 Debiopharm Sa Procede de preparation de complexes de metalloproteines et nouveaux derives de ceux-ci
WO1988007365A2 (fr) * 1987-04-01 1988-10-06 David F Ranney Support de medicaments a bio-adhesion pour absorption endotheliale et epitheliale et localisation d'agents therapeutiques et de diagnostic
EP0302473A2 (fr) * 1987-08-04 1989-02-08 Bristol-Myers Squibb Company Conjugues anticorps-enzyme associés à des prodrogues pour la libération d'agents cytotoxyques dans les cellules tumorales
WO1992000763A1 (fr) * 1990-07-03 1992-01-23 Akzo N.V. Compose immunoreactif
US5108759A (en) * 1987-04-01 1992-04-28 Ranney David F Endothelial envelopment drug carriers
WO1994013817A1 (fr) * 1992-12-04 1994-06-23 Me Medical Enzymes Ag Glutaminase produite par genie genetique et son utilisation en therapie antivirale et anticancereuse
US5672334A (en) * 1991-01-16 1997-09-30 Access Pharmaceuticals, Inc. Invivo agents comprising cationic metal chelators with acidic saccharides and glycosaminoglycans
US5707604A (en) * 1986-11-18 1998-01-13 Access Pharmaceuticals, Inc. Vivo agents comprising metal-ion chelates with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles
US6106866A (en) * 1995-07-31 2000-08-22 Access Pharmaceuticals, Inc. In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites
WO2002089852A1 (fr) * 2001-05-10 2002-11-14 Bio Vector Solutions Limited Systemes de polymeres proteiques solubles destines a l'administration de medicament

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987003205A1 (fr) * 1985-11-22 1987-06-04 Coral Sociedade Brasileira De Pesquisas E Desenvol Anticorps couples a une enzyme
FR2603287A1 (fr) * 1986-06-02 1988-03-04 Debiopharm Sa Procede de preparation de complexes de metalloproteines et nouveaux derives de ceux-ci
BE1002130A3 (fr) * 1986-06-02 1990-07-24 Debiopharm Sa Procede de preparation de complexes de metalloproteines et nouveaux derives de ceux-ci.
US5707604A (en) * 1986-11-18 1998-01-13 Access Pharmaceuticals, Inc. Vivo agents comprising metal-ion chelates with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles
US5108759A (en) * 1987-04-01 1992-04-28 Ranney David F Endothelial envelopment drug carriers
WO1988007365A2 (fr) * 1987-04-01 1988-10-06 David F Ranney Support de medicaments a bio-adhesion pour absorption endotheliale et epitheliale et localisation d'agents therapeutiques et de diagnostic
WO1988007365A3 (fr) * 1987-04-01 1988-11-17 David F Ranney Support de medicaments a bio-adhesion pour absorption endotheliale et epitheliale et localisation d'agents therapeutiques et de diagnostic
US4925678A (en) * 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
AU607494B2 (en) * 1987-04-01 1991-03-07 Access Pharmaceuticals, Inc. Biodadhesion drug carriers for endothelial and epithelial uptake and lesional localization of therapeutic and diagnostic agents
EP0302473A2 (fr) * 1987-08-04 1989-02-08 Bristol-Myers Squibb Company Conjugues anticorps-enzyme associés à des prodrogues pour la libération d'agents cytotoxyques dans les cellules tumorales
EP0302473A3 (en) * 1987-08-04 1990-01-17 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
WO1992000763A1 (fr) * 1990-07-03 1992-01-23 Akzo N.V. Compose immunoreactif
US5672334A (en) * 1991-01-16 1997-09-30 Access Pharmaceuticals, Inc. Invivo agents comprising cationic metal chelators with acidic saccharides and glycosaminoglycans
US7052689B2 (en) 1991-12-04 2006-05-30 Me Medical Enzymes Ag Method for producing therapeutically suitable glutaminase
WO1994013817A1 (fr) * 1992-12-04 1994-06-23 Me Medical Enzymes Ag Glutaminase produite par genie genetique et son utilisation en therapie antivirale et anticancereuse
US6312939B1 (en) 1992-12-04 2001-11-06 Me Medical Enzymes Ag Genetically engineered glutaminase and its use in antiviral and anticancer therapy
US6106866A (en) * 1995-07-31 2000-08-22 Access Pharmaceuticals, Inc. In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites
WO2002089852A1 (fr) * 2001-05-10 2002-11-14 Bio Vector Solutions Limited Systemes de polymeres proteiques solubles destines a l'administration de medicament

Similar Documents

Publication Publication Date Title
US4749570A (en) Targeting conjugates of albumin and therapeutic agents
Aplin et al. Preparation, Properties, and Applications of Carbohydrate Conjugates of Proteins and Lipid
US5853723A (en) Targeting of peg antibody conjugates to islet cells
US4847240A (en) Method of effecting cellular uptake of molecules
Fujita et al. Targeted delivery of human recombinant superoxide dismutase by chemical modification with mono-and polysaccharide derivatives.
US5087616A (en) Cytotoxic drug conjugates and their delivery to tumor cells
CA1168150A (fr) Conjugats d'albumine et d'agents therapeutiques
Simpson et al. Insulin receptor phosphorylation may not be a prerequisite for acute insulin action
EP0031999B1 (fr) Protéine hybride antitumeur et procédé pour sa préparation
US4701521A (en) Method of effecting cellular uptake of molecules
Muzykantov et al. Immunotargeting of antioxidant enzyme to the pulmonary endothelium.
US5433946A (en) Synthesis and utilization of therapeutic agents for the treatment of lysosomal storage diseases
WO1994013311A1 (fr) Conjugues enzymes-polymeres glycolipidiques
AU595173B2 (en) Method and use for site-specific activation of substances
Lee et al. Neoglycoproteins as probes for binding and cellular uptake of glycoconjugates
Tsukada et al. An anti-α-fetoprotein antibody-daunorubicin conjugate with a novel poly-L-glutamic acid derivative as intermediate drug carrier
Poznansky et al. Insulin: carrier potential for enzyme and drug therapy
FI97692C (fi) Menetelmä terapeuttisesti käyttökelpoisen aktivaattori-kohdistusosa -konjugaatin ja esilääkkeen valmistamiseksi
Poznansky [50] Soluble enzyme-albumin conjugates: New possibilities for enzyme replacement therapy
Wileman Properties of asparaginase-dextran conjugates
US4911911A (en) Ribosome-inactivating glycoproteins, modified by oxidation of their osidic units and formation of a schiff's base and in-vivo prolonged action immunotoxins containing such a glycoprotein
CA1264667A (fr) Procede de preparation d'immunotoxines a action prolongee contenant un glycopeptide qui inactive les ribosomes, ledit glycopeptide etant modifie au niveau de ses unites polysaccharidiques
Meijer et al. The role of the liver in clearance of glycoproteins from the general circulation, with special reference to intestinal alkaline phosphatase
AU652939B2 (en) Targeted protection from cytotoxins
Poznansky Enzyme-protein conjugates: new possibilities for enzyme therapy

Legal Events

Date Code Title Description
MKEX Expiry